Coralcal-Kit

Coralcal-Kit is a combination product used in the management of postmenopausal osteoporosis, combining a bisphosphonate with calcium and vitamin D3 to support adequate mineral intake during antiresorptive therapy.

Established / Guideline-Supported Uses

• Treatment of postmenopausal osteoporosis — to increase bone mineral density and reduce the risk of vertebral fractures.
• Prevention of postmenopausal osteoporosis — in women at increased risk of bone loss, particularly around or after menopause.

Adjunct Role of Calcium Carbonate and Vitamin D3

The calcium carbonate and vitamin D3 components are included as adjunct therapy to correct or prevent dietary calcium and vitamin D insufficiency, which is required for the bisphosphonate component of Coralcal-Kit to work effectively and safely. They are not a substitute for the antiresorptive effect of the ibandronic acid component.

Coralcal-Kit is not indicated for use in men, in premenopausal women, or for glucocorticoid-induced osteoporosis, and has not been established as effective for these uses.

Each formulation of Ibandronic Acid + Calcium Carbonate + Vitamin D3 typically provides:

• Ibandronic acid (as ibandronate sodium) — a nitrogen-containing bisphosphonate.
• Calcium carbonate — an elemental calcium source.
• Vitamin D3 (cholecalciferol) — to support calcium absorption and bone mineralization.

Exact strengths and the split between a once-monthly bisphosphonate tablet and daily calcium/vitamin D3 tablets vary by brand and pack presentation; refer to the specific product label for exact quantities.

Coralcal-Kit is a combination bone-health product intended for postmenopausal women who require both antiresorptive treatment and adequate calcium/vitamin D status. It pairs ibandronic acid, a potent nitrogen-containing bisphosphonate, with calcium carbonate and vitamin D3 (cholecalciferol) to ensure the mineral substrate necessary for bone remodeling is available while osteoclast-mediated bone breakdown is suppressed.

This type of combination is used because bisphosphonates are most effective and safest when the patient is not calcium- or vitamin D-deficient; correcting these deficiencies reduces the risk of treatment-related hypocalcemia and supports the bone density benefits of therapy.

Coralcal-Kit belongs to the therapeutic class of bone resorption inhibitors (bisphosphonates) combined with calcium and vitamin D supplements. It is classified under agents used for the treatment and prevention of osteoporosis and disorders of bone metabolism.

Ibandronic Acid

Ibandronic acid, the bisphosphonate component of Ibandronic Acid + Calcium Carbonate + Vitamin D3, binds strongly to bone hydroxyapatite and selectively inhibits osteoclast-mediated bone resorption without directly interfering with bone formation. Over time this shifts the balance of bone remodeling toward net bone mineral gain, increasing bone mineral density and reducing fracture risk, particularly at the spine.

Calcium Carbonate

Calcium carbonate dissociates in the acidic environment of the stomach to release elemental calcium, which is absorbed in the small intestine and used for bone mineralization and numerous physiological processes including neuromuscular function and coagulation.

Vitamin D3 (Cholecalciferol)

Vitamin D3 is hydroxylated in the liver and kidney to its active form, which promotes intestinal absorption of calcium and phosphate, supports normal bone mineralization, and helps maintain serum calcium within the normal range — reducing the risk of hypocalcemia during bisphosphonate therapy.

Coralcal-Kit (bisphosphonate component) must be taken orally on an empty stomach with plain water only, first thing in the morning, at least 60 minutes before any other food, beverage, or medication, and the patient must remain upright for at least 60 minutes afterward. The calcium carbonate/vitamin D3 component is taken separately, on non-dosing days, generally with food to enhance calcium absorption, as directed on the product label.

Clinically significant interactions with Coralcal-Kit include the following:

• Calcium, antacids, and mineral supplements: Concomitant oral calcium (including that in Coralcal-Kit itself if timed incorrectly), aluminum/magnesium antacids, and other multivalent cation products significantly reduce absorption of the ibandronic acid component; these must be separated by at least 60 minutes.
• Oral bisphosphonate absorption generally: Any food or beverage other than plain water taken within 60 minutes of the ibandronic acid dose markedly reduces its absorption and efficacy.
• Tetracyclines and fluoroquinolone antibiotics: The calcium carbonate component can chelate these antibiotics and reduce their absorption; separate administration by several hours.
• NSAIDs and aspirin: Concurrent use may increase the risk of upper gastrointestinal irritation when combined with the bisphosphonate component.
• Thiazide diuretics: May increase the risk of hypercalcemia when combined with the calcium/vitamin D3 components.
• Digoxin and other cardiac glycosides: Hypocalcemia or hypercalcemia associated with calcium/vitamin D imbalance can affect cardiac sensitivity to digoxin; monitor calcium status.

Side effects of Coralcal-Kit may relate to either the bisphosphonate or the calcium/vitamin D3 components.

Common

• Upper gastrointestinal discomfort, dyspepsia, abdominal pain
• Musculoskeletal (back, joint, or muscle) pain
• Headache
• Constipation or diarrhea
• Mild, transient flu-like symptoms after the first dose

Less Common but Clinically Important

• Esophagitis, esophageal ulceration, or esophageal irritation (see Precautions)
• Osteonecrosis of the jaw (rare; see Precautions)
• Atypical femur fractures with long-term use (see Precautions)
• Hypocalcemia or, with excessive supplementation, hypercalcemia
• Ocular inflammation (uveitis, scleritis) — rare
• Severe allergic reactions, including angioedema — rare

Coralcal-Kit is intended for use in postmenopausal women, and data on its use in pregnancy and lactation are very limited. Bisphosphonates are retained in bone for a prolonged period and are generally not recommended during pregnancy. Coralcal-Kit should be used in pregnancy only if clearly needed and the potential benefit justifies the potential risk to the fetus, and only under close physician guidance. It is not known whether ibandronic acid passes into breast milk; use during breastfeeding should be avoided unless specifically advised by a physician, who should weigh the benefits of treatment against potential risks to the infant.

Osteonecrosis of the Jaw (ONJ)

Rare cases of osteonecrosis of the jaw have been reported with bisphosphonates, including the ibandronic acid component of Coralcal-Kit, usually associated with tooth extraction and/or local infection with delayed healing. A dental examination is recommended before starting therapy in patients with risk factors.

Atypical Femur Fractures

Atypical, low-trauma subtrochanteric and femoral shaft fractures have been reported with long-term bisphosphonate use. New thigh, hip, or groin pain should be evaluated.

Esophageal and Gastrointestinal Irritation

The bisphosphonate component of Coralcal-Kit can cause esophageal irritation, esophagitis, or ulceration. Strict adherence to dosing instructions (upright posture, plain water, 60-minute fasting window) reduces this risk. Discontinue and seek medical advice if symptoms of esophageal irritation (dysphagia, new or worsening heartburn, chest pain) develop.

Hypocalcemia

Pre-existing hypocalcemia must be corrected before starting Coralcal-Kit. Adequate calcium and vitamin D intake, supported by the combination's own calcium carbonate and vitamin D3 content, should be maintained throughout treatment.

Renal Function

Use with caution in mild-to-moderate renal impairment; avoid in severe renal impairment.

Hypercalcemia Risk from Calcium/Vitamin D3

Excessive intake of calcium or vitamin D3 beyond recommended doses can cause hypercalcemia or hypervitaminosis D; avoid additional calcium/vitamin D supplementation unless directed by a physician.

Overdose of the bisphosphonate component of Coralcal-Kit may cause hypocalcemia, upper gastrointestinal irritation, esophagitis, gastritis, or ulceration. Overdose of the calcium carbonate/vitamin D3 component may cause hypercalcemia, with symptoms such as nausea, vomiting, constipation, confusion, or abnormal heart rhythm.

In case of suspected overdose, seek immediate medical attention or contact emergency services/a poison control center. Milk or antacids may be given to bind the bisphosphonate if a recent oral overdose is identified and the patient can safely swallow, but the patient should be kept upright to reduce the risk of esophageal irritation, and induced vomiting should not be attempted. Definitive management should be directed by a physician or emergency medical service, generally with monitoring of serum calcium.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

Elderly

Coralcal-Kit is primarily used in postmenopausal (typically older) women; no specific dose adjustment is required based on age alone, but renal function should be assessed.

Renal Impairment

No dose adjustment is needed in mild-to-moderate renal impairment. Coralcal-Kit is contraindicated in severe renal impairment (see Contraindications).

Hepatic Impairment

No specific dose adjustment has been established as necessary; limited data are available.

Pediatric Population

Coralcal-Kit is not indicated for use in children or adolescents; safety and efficacy in this population have not been established.

Men

Coralcal-Kit is not established as effective for osteoporosis treatment in men and is not indicated for this population.

The optimal duration of treatment with Coralcal-Kit has not been definitively established for all patients. Bisphosphonate therapy is typically continued for several years, with periodic reassessment (for example, after 3–5 years) of ongoing fracture risk to determine whether continued therapy, a treatment pause ("drug holiday"), or an alternative approach is appropriate. Calcium and vitamin D3 supplementation is generally continued for as long as the bisphosphonate component is used, and often beyond, based on dietary intake and individual needs. Duration should be individualized by the treating physician.

Bisphosphonate (bone resorption inhibitor) in fixed combination with calcium and vitamin D3 supplement

The ibandronic acid component of Ibandronic Acid + Calcium Carbonate + Vitamin D3 is a nitrogen-containing bisphosphonate that binds to bone mineral and is taken up by osteoclasts, where it inhibits farnesyl pyrophosphate synthase in the mevalonate pathway. This impairs osteoclast function and survival, reducing bone resorption and shifting bone remodeling toward net mineral retention. The calcium carbonate and vitamin D3 components provide substrate and support intestinal calcium absorption, respectively, ensuring adequate mineral availability for bone formation and reducing the risk of treatment-associated hypocalcemia.

C

Coralcal-Kit is not indicated for use in pediatric patients. Safety and efficacy of the ibandronic acid component in children and adolescents have not been established, and bisphosphonates are generally avoided in growing bone unless used for specific pediatric metabolic bone disorders under specialist supervision, which is outside the approved use of Coralcal-Kit.